Truvestments Capital’s Pliant Therapeutics PLRX Stock Holding History

Truvestments Capital’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$57	Hold	50	–	–	﹤0.01%	1119
2026 Q1	$63	Hold	50	–	–	﹤0.01%	1140
2025 Q4	$61	Hold	50	–	–	﹤0.01%	996
2025 Q3	$74	Sell	50 -117	-70%	-$179	﹤0.01%	1003
2025 Q2	$194	Hold	167	–	–	﹤0.01%	927
2025 Q1	$225	Hold	167	–	–	﹤0.01%	990
2024 Q4	$2.2K	Hold	167	–	–	﹤0.01%	828
2024 Q3	$1.87K	Buy	+167	New	+$2.09K	﹤0.01%	805
2024 Q2	–	Sell	-184	Closed	-$2.74K	–	552
2024 Q1	$2.74K	Hold	184	–	–	﹤0.01%	592
2023 Q4	$3.33K	Hold	184	–	–	﹤0.01%	642
2023 Q3	$3.19K	Hold	184	–	–	﹤0.01%	555
2023 Q2	$3.33K	Hold	184	–	–	﹤0.01%	563
2023 Q1	$4.89K	Buy	+184	New	+$5.24K	﹤0.01%	514

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Truvestments Capital's PLRX Position: Q2 2026 in Review

Truvestments Capital held its Pliant Therapeutics (PLRX) position steady in Q2 2026 at 50 shares worth $57. The position accounts for ﹤0.01% of the portfolio, ranked #1119.

Truvestments Capital first reported a position in PLRX in Q1 2023 and has held it in 13 quarters since. The position peaked at $4.89K in Q1 2023. 86 funds tracked by Wall St. Rank hold PLRX as of Q2 2026.

Truvestments Capital held 50 shares of Pliant Therapeutics worth $57 as of Q2 2026.
Truvestments Capital left its Pliant Therapeutics share count unchanged in Q2 2026.
Pliant Therapeutics made up ﹤0.01% of Truvestments Capital's portfolio in Q2 2026, its #1119 holding.
Truvestments Capital first reported a position in Pliant Therapeutics in Q1 2023 and has held it in 13 quarters since.
Truvestments Capital's Pliant Therapeutics position peaked at $4.89K in Q1 2023.
86 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.